Meeting
2012 ASCO Annual Meeting
Cilengitide with cetuximab, cisplatin, and 5-FU in recurrent and/or metastatic squamous cell cancer of the head and neck: The ADVANTAGE phase II trial.
Authors
Jan Baptist Vermorken
Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
Jan Baptist Vermorken , Frederic Peyrade , Juergen Krauss , Ricard Mesia , Eva Remenar , Thomas C. Gauler , Ulrich Keilholz , Jean-Pierre Delord , Philippe Schafhausen , Jozsef Erfán , Tim H. Brummendorf , Lara Iglesias , Ullrich Bethe , Guillaume de La Bourdonnaye , Paul M. Clement
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00705016
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5516^)
Abstract #
5516^
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
First Author: Makoto Tahara
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2023 ASCO Annual Meeting
A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.
First Author: A. Dimitrios Dimitrios Colevas
Poster
2020 ASCO Virtual Scientific Program
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
First Author: Christine H. Chung